vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Natural Grocers by Vitamin Cottage, Inc. (NGVC). Click either name above to swap in a different company.
Natural Grocers by Vitamin Cottage, Inc. is the larger business by last-quarter revenue ($335.6M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 1.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Natural Grocers by Vitamin Cottage, Inc. is a U.S.-based specialty retail chain that offers certified organic groceries, dietary supplements, natural personal care items, and eco-friendly household products. It serves health-conscious consumers across multiple U.S. states, following strict quality standards that exclude artificial preservatives, colors, flavors and harmful additives.
ESPR vs NGVC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $335.6M |
| Net Profit | — | $11.3M |
| Gross Margin | — | 29.5% |
| Operating Margin | 50.6% | 4.4% |
| Net Margin | — | 3.4% |
| Revenue YoY | 143.7% | 1.6% |
| Net Profit YoY | — | 14.0% |
| EPS (diluted) | $0.32 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $335.6M | ||
| Q3 25 | $87.3M | $336.1M | ||
| Q2 25 | $82.4M | $328.7M | ||
| Q1 25 | $65.0M | $335.8M | ||
| Q4 24 | $69.1M | $330.2M | ||
| Q3 24 | $51.6M | $322.7M | ||
| Q2 24 | $73.8M | $309.1M | ||
| Q1 24 | $137.7M | $308.1M |
| Q4 25 | — | $11.3M | ||
| Q3 25 | $-31.3M | $11.8M | ||
| Q2 25 | $-12.7M | $11.6M | ||
| Q1 25 | $-40.5M | $13.1M | ||
| Q4 24 | — | $9.9M | ||
| Q3 24 | $-29.5M | $9.0M | ||
| Q2 24 | $-61.9M | $9.2M | ||
| Q1 24 | $61.0M | $8.0M |
| Q4 25 | — | 29.5% | ||
| Q3 25 | — | 29.5% | ||
| Q2 25 | — | 29.9% | ||
| Q1 25 | — | 30.3% | ||
| Q4 24 | — | 29.9% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 29.3% |
| Q4 25 | 50.6% | 4.4% | ||
| Q3 25 | -11.4% | 4.6% | ||
| Q2 25 | 8.6% | 4.7% | ||
| Q1 25 | -34.0% | 5.2% | ||
| Q4 24 | -6.4% | 4.0% | ||
| Q3 24 | -31.0% | 3.7% | ||
| Q2 24 | 3.5% | 4.2% | ||
| Q1 24 | 52.5% | 3.7% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | -35.9% | 3.5% | ||
| Q2 25 | -15.4% | 3.5% | ||
| Q1 25 | -62.2% | 3.9% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -57.2% | 2.8% | ||
| Q2 24 | -83.9% | 3.0% | ||
| Q1 24 | 44.3% | 2.6% |
| Q4 25 | $0.32 | $0.49 | ||
| Q3 25 | $-0.16 | $0.51 | ||
| Q2 25 | $-0.06 | $0.50 | ||
| Q1 25 | $-0.21 | $0.56 | ||
| Q4 24 | $-0.14 | $0.43 | ||
| Q3 24 | $-0.15 | $0.38 | ||
| Q2 24 | $-0.33 | $0.40 | ||
| Q1 24 | $0.34 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $23.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $220.0M |
| Total Assets | $465.9M | $668.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $23.2M | ||
| Q3 25 | $92.4M | $17.1M | ||
| Q2 25 | $86.1M | $13.2M | ||
| Q1 25 | $114.6M | $21.2M | ||
| Q4 24 | $144.8M | $6.3M | ||
| Q3 24 | $144.7M | $8.9M | ||
| Q2 24 | $189.3M | $13.9M | ||
| Q1 24 | $226.6M | $11.0M |
| Q4 25 | $-302.0M | $220.0M | ||
| Q3 25 | $-451.4M | $212.4M | ||
| Q2 25 | $-433.5M | $202.5M | ||
| Q1 25 | $-426.2M | $193.0M | ||
| Q4 24 | $-388.7M | $181.9M | ||
| Q3 24 | $-370.2M | $174.3M | ||
| Q2 24 | $-344.2M | $167.8M | ||
| Q1 24 | $-294.3M | $160.0M |
| Q4 25 | $465.9M | $668.6M | ||
| Q3 25 | $364.0M | $670.5M | ||
| Q2 25 | $347.1M | $659.0M | ||
| Q1 25 | $324.0M | $664.6M | ||
| Q4 24 | $343.8M | $648.9M | ||
| Q3 24 | $314.1M | $655.5M | ||
| Q2 24 | $352.3M | $654.4M | ||
| Q1 24 | $373.1M | $656.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $21.1M |
| Free Cash FlowOCF − Capex | — | $11.6M |
| FCF MarginFCF / Revenue | — | 3.4% |
| Capex IntensityCapex / Revenue | 0.0% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $42.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $21.1M | ||
| Q3 25 | $-4.3M | $15.6M | ||
| Q2 25 | $-31.4M | $2.9M | ||
| Q1 25 | $-22.6M | $34.1M | ||
| Q4 24 | $-35.0M | $2.7M | ||
| Q3 24 | $-35.3M | $24.5M | ||
| Q2 24 | $-7.2M | $12.4M | ||
| Q1 24 | $53.8M | $20.2M |
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $7.5M | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $27.6M | ||
| Q4 24 | — | $-6.9M | ||
| Q3 24 | $-35.5M | $18.0M | ||
| Q2 24 | $-7.3M | $3.6M | ||
| Q1 24 | $53.8M | $9.8M |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | -1.3% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | -68.7% | 5.6% | ||
| Q2 24 | -9.9% | 1.2% | ||
| Q1 24 | 39.0% | 3.2% |
| Q4 25 | 0.0% | 2.9% | ||
| Q3 25 | 0.0% | 2.4% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 2.9% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | 0.1% | 2.9% | ||
| Q1 24 | 0.1% | 3.4% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 1.32× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 2.60× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | 2.72× | ||
| Q2 24 | — | 1.35× | ||
| Q1 24 | 0.88× | 2.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
